BridgeBio has substantially boosted its development of an new solution for cardiac amyloidosis, utilizing Attruby. Preliminary trial data suggests promising benefits for individuals diagnosed with the debilitating condition. The effort underscores BridgeBio's focus to addressing significant healthcare demands in a cardiology field. Attr… Read More